HC Wainwright & Co. Reiterates Buy on LAVA Therapeutics, Maintains $6 Price Target
LAVA Therapeutics NV +1.75% Pre
LAVA Therapeutics NV LVTX | 2.04 2.04 | +1.75% 0.00% Pre |
HC Wainwright & Co. analyst Arthur He reiterates LAVA Therapeutics (NASDAQ:
LVTX) with a Buy and maintains $6 price target.